http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Yu, K‐,H.,Hong, K‐,S.,Lee, B‐,C.,Oh, M‐,S.,Cho, Y‐,J.,Koo, J‐,S.,Park, J‐,M.,Bae, H‐,J.,Han, M‐,K.,Ju, Y‐,S.,Kang, D‐,W.,Appelros, P. Blackwell Publishing Ltd 2011 Acta neurologica Scandinavica Vol.123 No.5
<P>Yu K‐H, Hong K‐S, Lee B‐C, Oh M‐S, Cho Y‐J, Koo J‐S, Park J‐M, Bae H‐J, Han M‐K, Ju Y‐S, Kang D‐W, Appelros P, Norrving B, Terent A. Comparison of 90‐day case‐fatality after ischemic stroke between two different stroke outcome registries using propensity score matching analysis. Acta Neurol Scand: 2011: 123: 325–331. © 2010 John Wiley & Sons A/S.</P><P><B>Background – </B> It has not been clarified whether the disparity in ischemic stroke outcome between populations is caused by ethnic and geographic differences or by variations in case mix. Propensity score matching (PSM) analysis can overcome some analytical problems but is rarely used in stroke outcome research. This study was to compare the ischemic stroke case‐fatality between two PSM cohorts of Sweden and Korea.</P><P><B>Methods – </B> Prognostic variables related to baseline characteristics and stroke care were included in our PSM model. Then, we selected 7675 Swedish and 1220 Korean patients with ischemic stroke from each stroke registers and performed one‐to‐one matching based on propensity scores of each patient.</P><P><B>Results – </B> After PSM, all measured variables were well balanced in 1163 matched subjects, and the 90‐day case‐fatality was identical 6.2% (HR 0.997, 95%CI 0.905–1.099) in Sweden and Korea.</P><P><B>Conclusions – </B> No difference is found in the 90‐day case‐fatality in propensity score‐matched Swedish and Korean patients with ischemic stroke.</P>
Park, S R,Kong, S-Y,Nam, B-H,Choi, I J,Kim, C G,Lee, J Y,Cho, S J,Kim, Y W,Ryu, K W,Lee, J H,Rhee, J,Park, Y-I,Kim, N K Nature Publishing Group 2011 The British journal of cancer Vol.104 No.7
<P><B>Background:</B></P><P>We evaluated the association between polymorphisms of cytochrome P450 2A6 (<I>CYP2A6</I>)/excision repair cross-complementation group 1 (<I>ERCC1</I>)/X-ray repair cross-complementing group 1(<I>XRCC1</I>) and treatment outcomes of metastatic gastric cancer (MGC) patients treated with S-1/cisplatin.</P><P><B>Methods:</B></P><P>Among MGC patients (<I>n</I>=108), who received S-1 (40 mg m<SUP>−2</SUP> b.i.d., days 1–14) and cisplatin (60 mg m<SUP>−2</SUP>, day 1) every 3 weeks, we analysed the wild-type allele (<I>W</I>) and variants (<I>V</I>) of <I>CYP2A6</I> (<I>*4</I>, <I>*7, *9, *10</I>), and the polymorphisms of <I>ERCC1</I> (rs11615, rs3212986) and <I>XRCC1</I> (rs25487).</P><P><B>Results:</B></P><P>Patients having fewer <I>CYP2A6</I> variants had better response rates (<I>W</I>/<I>W vs W</I>/<I>V</I> other than <I>*1/*4 vs V</I>/<I>V</I> or <I>*1/*4</I>=66.7 <I>vs</I> 58.3 <I>vs</I> 32.3% <I>P</I>=0.008), time to progression (TTP) (7.2 <I>vs</I> 6.1 <I>vs</I> 3.5 months, <I>P</I>=0.021), and overall survival (23.2 <I>vs</I> 15.4 <I>vs</I> 12.0 months, <I>P</I>=0.004). <I>ERCC1 19442C</I>><I>A</I> (rs3212986) was also associated with response rate (<I>C/C</I>, 46.7% <I>vs C/A</I>, 55.3% <I>vs A/A</I>, 87.5%) (<I>P</I>=0.048) and TTP (4.4 <I>vs</I> 7.6 <I>vs</I> 7.9 months) (<I>P</I>=0.012). Patients carrying both risk genotypes of <I>CYP2A6</I> (<I>V</I>/<I>V</I> or <I>1/*4</I>) and <I>ERCC1 19442C</I>><I>A</I> (<I>C/C</I>) <I>vs</I> those carrying none showed an adjusted odds ratio of 0.113 (<I>P</I>=0.004) for response, and adjusted hazard ratios of 3.748 (<I>P</I>=0.0001) for TTP and 2.961 (<I>P</I>=0.006) for death.</P><P><B>Conclusion:</B></P><P>Polymorphisms of <I>CYP2A6</I> and <I>ERCC1 19442C</I>><I>A</I> correlated with the efficacy of S-1/cisplatin.</P>
Kang, B.Y.,Lee, S.S.,Song, M.S.,Cho, K.K.,Han, S.H.,Cho, B.K. Elsevier 2016 Current Applied Physics Vol.16 No.9
<P>Emergence of anomalous weak ferromagnetism in geometrically frustrated magnetic system of R1-xYxB4 (R = Tb and Dy) is quite interesting [Phys. Rev. B 91, 024414 (2015)]. In order to study the weak ferromagnetism in other compounds, the magnetic properties of R1-xYxB4 (R = Sm, Gd, and Er) were investigated. The anomalous weak ferromagnetism was also found to occur in all compounds, R1-xYxB4 (R = Sm, Gd, and Er). The weak ferromagnetism is revealed in the magnetic easy plane, (001), for R1-xYxB4 (R = Sm and Gd) and along the magnetic easy axis, [001], for R1-xYxB4 (R = Er). The magnitude of saturated magnetic moment at T = 2 K shows a strong dependence on Y-concentration, i.e., the maximum magnitude occurs at x approximate to 0.3 for all compounds. The general magnetic properties of weak ferromagnetism is quite similar to the weak ferromagnetism in R1-xYxB4 (R = Tb, Dy). Therefore, it is experimentally demonstrated that the emergence of weak ferromagnetism, induced by non-magnetic substitution in a magnetically frustrated system, is the universal feature in RB4 compounds. (C) 2016 Elsevier B.V. All rights reserved.</P>
Koo, B. K.,Cho, Y. M.,Park, B. L.,Cheong, H. S.,Shin, H. D.,Jang, H. C.,Kim, S. Y.,Lee, H. K.,Park, K. S. Blackwell Publishing Ltd 2007 Diabetic medicine Vol.24 No.2
<P>Abstract</P><P>Aims </P><P>Kir6.2 is found in the pancreatic B-cell, cardiac and skeletal muscle and non-vascular smooth muscle. <I>KCNJ11</I>, encoding Kir6.2, has been shown to be associated with both Type 2 diabetes mellitus and cardiovascular disease in several populations. In this study, we investigated whether polymorphisms in <I>KCNJ11</I> are associated with Type 2 diabetes and other metabolic phenotypes in the Korean population.</P><P><B>Methods </B></P><P>We sequenced <I>KCNJ11</I> to identify common polymorphisms using 24 Korean DNA samples. Of the 14 polymorphisms found in <I>KCNJ11</I>, six common ones [genomic sequence (g.)−1709A>T, g.−1525T>C, g.67G>A (E23K), g.570C>T (A190A), g.1009A>G (I337V), and g.1388C>T] were genotyped in 761 Type 2 diabetic patients and in 630 non-diabetic subjects.</P><P><B>Results</B> </P><P>All the polymorphic loci in <I>KCNJ11</I> are in strong linkage disequilibrium in the Korean population and act as one haplotype block. g.67G>A and g.1009A>G were associated with an increased risk of Type 2 diabetes [age, sex, and body mass index (BMI)-adjusted odds ratios (OR) = 1.376 (1.085–1.745), <I>P</I> = 0.008 and 1.411 (1.111–1.791), <I>P</I> = 0.005, respectively], as was one haplotype (A-T-A-C-G-C in the order of polymorphisms as shown above) containing g.67A and g.1009G [OR = 1.359 (1.080–1.709), <I>P</I> = 0.009]. The haplotype (A-T-A-C-G-C) was also strongly associated with hypertension [OR = 1.655 (1.288–2.126), <I>P</I> < 0.001].</P><P><B>Conclusions </B></P><P>Polymorphisms in <I>KCNJ11</I> are associated with Type 2 diabetes and also with hypertension in the Korean population.</P>
Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect
Choi, K-J,Kim, J-H,Lee, Y-S,Kim, J,Suh, B-S,Kim, H,Cho, S,Sohn, J-H,Kim, G E,Yun, C-O Nature Publishing Group 2006 Gene therapy Vol.13 No.13
Oncolytic adenoviral vectors are currently being developed as biologic anticancer agents. Coupling the lytic function of an oncolytic adenovirus (Ad) with its ability as a transgene delivery system represents a powerful extension of this methodology. A clear advantage is the amplification of a therapeutic gene, as replicating vectors would be able to infect and deliver the gene of interest to neighboring cells. Granulocyte–macrophage colony-stimulating factor (GM-CSF) is one of the most potent stimulators of a specific and long-lasting antitumor immunity and its important role in the maturation of antigen-presenting cells to induce T-cell activation has been well documented. Similarly, the B7 family has also been shown to play an integral role in mediating an antitumor response. Most tumor cells, however, lack the expression of these costimulatory molecules on their surface, thus escaping immune system recognition. To increase the antitumor effect of an oncolytic Ad, we have generated an E1B 55 kDa-deleted oncolytic adenoviral vector, YKL-GB, that expresses both GM-CSF and B7-1. The therapeutic efficacy of YKL-GB Ad was evaluated in immunocompetent mice bearing murine melanoma B16-F10 tumors. Significant inhibition of tumor growth was seen in mice treated with YKL-GB compared to those treated with the analogous vector, YKL-1. Moreover, YKL-GB oncolytic Ad demonstrated enhanced antitumor activity and higher incidences of tumor regression compared to a replication-incompetent Ad, dl-GB, which coexpresses GM-CSF and B7-1. Localized GM-CSF and B7-1 gene transfer also conferred long-lasting immunity against a tumor re-challenge. To establish that the observed antitumor effect is associated with the generation of a tumor-specific immune response, we carried out interferon-γ enzyme-linked immune spot assay. We observed that YKL-GB induced significantly higher immune cell activation than YKL-1. Furthermore, immunohistochemical studies demonstrated robust dendritic cells and CD4<SUP>+</SUP>/CD8<SUP>+</SUP> T-cell infiltration in these mice compared to the YKL-1-treated groups. In agreement with these results, splenocytes from tumor-bearing mice treated with YKL-GB expressed high levels of the costimulatory and activation molecules. These findings demonstrate the effectiveness of enhancing the immune response against tumors with an oncolytic Ad expressing both GM-CSF and B7-1 and provide a potential therapeutic strategy for the management of neoplasia.Gene Therapy (2006) 13, 1010–1020. doi:10.1038/sj.gt.3302759; published online 9 March 2006
Y.S. Cho,Y.B. Kim,W.S. Park,C.S. Kim,T.K. Kim 한국자기학회 1995 韓國磁氣學會誌 Vol.5 No.5
The influence of Nd and B contents on the magnetic properties and structures of α-Fe based Nd-(Fe, Co)B-Mo-Cu alloys was investigated. Nd₄(Fe_(0.9)Co_(0.1))_(92-x)BxMo₃Cu₁ and Nd_x(Fe_(0.9)Co_(0.1))_(86-x)B_(10)Mo₃Cu₁ amorphous alloys prepared by rapid solidification process were crystallized to form nanocrystalline structure. The increase of B content in Nd₄(Fe_(0.9)Co_(0.1))_(92-x)BxMo₃Cu₁ nanocrystalline resulted in the change of structure of soft phase in the sequence of α-Fe → α-Fe+Fe₃B → Fe₃B. The coercivitis of the alloys were increased with increasing B content and was 263 kA/m at x=18. On the contrary, the remanence has shown an opposite trends. The increase of Nd content in Nd_x(Fe_(0.9)Co_(0.1))_(86-x)B_(10)Mo₃Cu₁ nanocrystalline containing α-Fe as main phase had no effect on the structure and improved coercivity up to 256 kA/m. However, the remanence was decreased from 1.4 T to 1.15 T according to the increase of Nd content.